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A R T I C L E  I N F O A B S T R A C T
MicroRNAs (miRNAs) are small, protein noncoding 
RNAs that regulate gene expression post-transcrip-
tionally. Their role is considered to set the gene ex-
pression to the optimal level, or in other words to pro-
vide “fine tuning” of gene expression. They regulate 
essential physiological processes such as differentia-
tion, cell growth, apoptosis and their role is known in 
tumor development too.
At tissue level differential miRNA expression in en-
docrine disorders including endocrine malignancies 
has also been reported. A new era of miRNAs-relat-
ed research started when miRNAs were successfully 
detected outside of cells, in biofluids, in cell-free en-
vironments. Their significant role has been demon-
strated in cell-cell communication in tumor biology.
Due to their stability circulating miRNAs can serve as 
potential biomarkers. In common diseases circulat-
ing miRNAs can be potentially proposed as screen-
ing biomarkers and they are also useful to detect 
tumor recurrence hence they can be applied in post-
surgery follow-up too. MiRNAs as diagnostic mark-
ers can also be helpful at tissue level when certain 
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histology diagnosis is challenging. Beside diag-
nosis, tissue miRNAs have the potential to pre-
dict prognosis.
Intensive research is carried out regarding en-
docrine tumors as well in terms of miRNAs. 
However, until now miRNAs as biomarkers do 
not applied in routine diagnostics, probably due 
to the challenging preanalytics. In this review 
we summarized tissue and circulating miRNAs 
found in thyroid, adrenal, pituitary and neuro-
endocrine tumors. We aimed to highlight the 
most important, selected miRNAs with poten-
tial diagnostic and prognostic value both in tis-
sue and circulation. Common miRNAs across 
different endocrine neoplasms are summarized 
and miRNAs enriched at 14q31 locus are also 
highlighted suggesting their general role in tu-
morigenesis of endocrine glands.

INTRODUCTION
MicroRNAs (miRNAs) are small, protein noncod-
ing RNAs that regulate gene expression post-
transcriptionally. Through RNA interference 
miRNAs target mRNAs mainly at 3’ untranslated 
regions but even the coding sequence or 5’UTR 
were described to be miRNA target regions 
[1]. After biogenesis the mature miRNA incor-
porates into miRNA-induced silencing complex 
(miRISC) [1]. In the miRISC complex, based on 
sequence complementarity miRNAs cause 
translational repression, mRNA destabilization 
or mRNA cleavage. However in some particular 
cases miRNAs can enhance gene expression as 
well [1]. It is thought that approximately 30-
50% of all protein-coding genes might be con-
trolled by miRNAs [2]. One miRNA potentially 
targets several transcripts, and one gene’s tran-
scription is influenced by numerous miRNAs. 
Therefore, the net physiological outcome is the 
result of a miRNA target network. Their role is 
considered to set the gene expression to the 
optimal level, or in other words provide “fine 
tuning” and adaptive setting of gene expression 
[3]. Their roles have been described in the regu-
lation of several physiological and pathophysi-
ological cellular processes such as proliferation, 
differentiation, metabolism and apoptosis.
A new era of miRNA-related research started 
when miRNAs’ presence was proved outside of 
cells, in biofluids. Henceforth extracellular miR-
NAs have been considered as a novel type of 
biomarkers that are secreted and can be taken 
up by various cells. Furthermore, as signal medi-
ators they can function similarly to hormones or 
cytokines. Several studies showed correlations 
between circulating miRNA dysregulation and 
pathophysiological conditions. Regarding neo-
plastic diseases extracellular miRNAs recently 
have been investigated and linked to diagnosis, 
prognosis and recurrence [4]. Differential miR-
NA expression in endocrine disorders including 
malignancies has also been reported [5, 6].
Extracellular (EC) miRNAs are secreted by near-
ly all kinds of cells and therefore they are de-
tectable practically in all body fluids [7]. As un-
protected miRNAs are sensitive to degradation 
mainly through RNAses present in large amount 
in these fluids, miRNAs in circulation are bound 
to proteins (mainly Argonaute (AGO)) or they 
are packaged into vesicles that protect miRNAs 
against degradation or cleavage. Based on size, 
EC vesicles are mainly categorized as exosomes, 
microvesicles or apoptotic bodies. Exosomes 
are small (approximately 30-100 nm) mem-
brane-limited secreted vesicles [8]. They are 
formed in the endosomal compartments of cell 
(multivesicular endosomes or MVEs) and can be 
released to extracellular space. Microvesicles 
are more variable in size, typically between 50-
1000 nm. They are generated by directly bud-
ding or shedding off the plasma membrane. 
Both exosomes and microvesicles contain vari-
ous molecules including mRNA, miRNA, pro-
teins, cytokines and different surface receptors 
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specific for their cell origin. Interestingly, several 
miRNAs were found in high density lipoprotein 
(HDL) particles as well [8].
Since their discovery there is exponentially 
increasing information regarding EC vesicle 
function. Studies showed their significant role 
in cell-cell communication in immunology and 
tumor biology. For instance, exosomes secret-
ed by dendritic cells carry antigens and are 
able to induce immune response [9]. They can 
mediate paracrine signals of cancer cells influ-
encing tumor microenvironment by exosome 
secretion in promoting growth by inhibiting 
antitumor immune response and by facilitat-
ing angiogenesis, cell migration and metasta-
sis [10]. Also, tumor cells were found to exhibit 
self-promoting effect by secreting microvesi-
cles [11]. However, gastric cancer cells were 
detected to eliminate tumor-suppressor miR-
NAs by exosome secretion [12].
On the whole, in a malignant tumor overex-
pressed (oncogenic) and downregulated (tu-
mor suppressor) miRNAs can be useful as po-
tential biomarkers. MiRNAs are tissue specific, 
they may be unique identifiers of certain tumor 
types both in tissue and in circulation. The pur-
pose of miRNA biomarkers can be various and 
they have a great potential in many ways. In 
frequent diseases, e.g., thyroid nodule (where 
prevalence is 2-6%, 19-35% and 8-65% by pal-
pation, ultrasound and autopsy, respectively) 
circulating miRNAs can be potentially recom-
mended as screening biomarkers [13]. miRNAs 
as diagnostic markers can also be helpful when 
cytology following fine-needle aspiration biop-
sy (FNAB) has to be performed, as from 3-6% 
to 10-25% of FNAB are interpreted as indeter-
minate without definitive diagnosis regarding 
thyroid tumors [13]. Additionally, in any tumor 
where histological diagnosis can be challenging 
(e.g. adrenal carcinoma or pheochromocytoma) 
miRNA biomarkers can be used to help diagno-
sis. Beside diagnosis, tissue miRNAs have the 
potential to predict prognosis and therapy re-
sponse as well. Circulating miRNAs are also use-
ful to detect tumor recurrence hence they can 
be applied in post-surgery follow-up.
In this review we focus on tissue and circulat-
ing miRNAs in thyroid, adrenal, pituitary and 
neuroendocrine tumors. Although the frame of 
this review cannot allow assessing all miRNAs 
in all the above mentioned neoplasms, for that 
many excellent reviews are available targeting a 
single tumor type, rather we would like to high-
light the most important, selected miRNAs as 
potential diagnostic and prognostic tissue and 
circulating biomarkers.
THYROID TUMORS
Thyroid cancer is the most frequent endocrine 
malignancy. The majority of thyroid tumors 
(~95%) arise from follicular cells and they are 
categorized as papillary (PTC, 75-80%) and 
follicular (FTC, 10-15%) or anaplastic thyroid 
cancer (ATC, 0.2-2%). Tumors developing from 
parafollicular C cells are called medullary thy-
roid cancer (MTC) representing ~5-10% of all 
thyroid cancers. Although commonly they occur 
sporadically, some of them (25-30%) are heredi-
tary and part of multiple endocrine neoplasia 
type 2 (MEN2), caused by germline mutations 
of the RET proto-oncogene [14]. Most of the 
well differentiated thyroid cancers (DTC, includ-
ing PTC, FTC) have excellent prognosis, however 
patients with ATC have 6-12 months’ median 
survival [13]. Thyroglobulin is widely applied as 
tumor marker for tumors arising from follicular 
cells. It is used for evaluation of tumor residuum 
or recurrence in patients treated by total thy-
roidectomy and/or radioidine ablation. On the 
other side calcitonin, a product of parafollicular 
C cells, is used for the diagnosis and follow-up 
of MTC. Both tumor markers have limitations 
therefore miRNAs can be practical in these dis-
eases too [15].
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Diagnostic miRNAs
Interestingly, global miRNA downregulation was 
detected in malignant thyroid cancer compared 
to normal tissue together with decreased DICER 
gene expression that was associated with ag-
gressive features [13, 15].
Since the first publication on miRNAs in thyroid 
cancer in 2005, numerous studies have been 
Authors
Panel 
of markers
Groups
n 
(sample 
number)
Sensitivity 
 (%)
Specificity 
(%)
Diagnostic 
accuracy 
(%)
Stokowy 
et al. 2016
miR-484, 
miR-184b-3p
mutation-
negative 
follicular thyroid 
carcinomas and 
follicular thyroid 
adenomas
44 89 87 na
Paskas 
et al. 2015
BRAF V600E, 
miR-221, 
miR-222, 
galectin-3
benign vs. 
malignant 
thyroid nodule
120 73.5 89.8 75.7
Panebianco 
et al. 2015
miR-146b, 
miR-222, 
KIT, TC1
benign vs. 
malignant 
thyroid nodule
118 92.3 94.7 96
Shen 
et al. 2012
miR-146b, 
miR-221, 
miR-187, 
miR-30d
benign vs. 
malignant 
thyroid nodule
68 88.9 78.3 85.3
Keutgen 
et al. 2012
miR-328, 
miR-222, 
miR-21, 
miR-197
benign vs. 
malignant 
thyroid lesions
72 100 86 90
Mazeh 
et al. 2012
miR-21, 
miR-31, 
miR-146b, 
miR-187, 
miR-221, 
miR-222
benign vs. 
malignant 
thyroid nodule
11 88 100 90
Table 1 miRNAs discriminating benign vs. malignant thyroid lesions 
from FNAB samples
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published and extensively reviewed e.g., by 
Malek et al. and Celano et al. in 2017. Among 
several miRNA alterations described, recent 
meta-analyses emphasize the role of couple 
of commonly upregulated miRNAs: miR-146b, 
miR-221, miR-222, miR-181b in PTC compared 
to normal tissue [13, 15]. Regarding the role of 
some of these miRNAs, downregulation of KIT 
was identified as the common potential regulat-
ing mechanism [16]. In FTC, miR-637, miR-181c-
3p, miR-206, and miR-7-5p were discovered as 
de novo potential FTC markers based on an-
other meta-analysis comprising 3 independent 
datasets [17]. In anaplastic thyroid cancer, simi-
larly to DTC cases, overexpression of miR-146b, 
miR-221, and miR-222 was described together 
with downregulation of miR-200 and miR-30 
families leading to enhanced epithelial-to-mes-
enchymal transition (EMT) [18]. miRNAs have 
been dysregulated in MTC too, and this dysreg-
ulation was described as a probable early event 
in C-cell carcinogenesis [19]. Similar to ATC, the 
underexpressed miR-200 family through regu-
lating E-cadherin by directly targeting ZEB1 (zinc 
finger E-box binding homeobox 1) and (ZEB2 
zinc finger E-box binding homeobox 2) leads to 
enhanced expression of transforming growth 
factor β (TGFβ)-2 and TGFβ-1 [13, 15].
Apart from tissue samples fine needle aspira-
tion biopsy (FNAB) specimens were also sub-
jected to miRNA analysis and yielded highly 
comparable results [15]. Meta-analyses showed 
that multiple miRNA assays showed a higher di-
agnostic accuracy than single miRNA and the 
test results indicated 77% sensitivity, 75% speci-
ficity with 0.83 AUC in a receiver operating char-
acteristic analysis [20]. However, several other 
studies reported promising sets of miRNAs in 
discriminating benign vs. malignant thyroid le-
sions from FNAB samples (Table 1).
Circulating miRNAs in both serum and plasma 
were tested and excellently summarized by 
Celano et al. Although the summary reported 
a highly variable miRNA expression [15], some 
miRNAs were identified by multiple groups. In 
PTC patients, the levels of miR-146b, miR-221 
and miR-222 were detected to be higher com-
pared to controls [13, 15, 21]. Post-surgically, 
significantly reduced miR-151 and miR-222 ex-
pression was reported compared to pre-opera-
tive samples in more than one study [21]. Also, 
miR-146b reportedly discriminated benign and 
malignant tumors with 61.4% sensitivity and 
74.3% specificity, while miR-155 had 57.9% sen-
sitivity and 63.2% specificity in serum/plasma 
[13, 15]. The levels of these two miRNAs were 
also correlated with lymph node metastases 
and tumor size [13, 15].
Plasma exosomal miRNAs were also assessed 
and miR-31 was found to be over-represented 
in the samples of patients with PTC compared 
to benign tumors, while miR-21 helped to dis-
tinguish between FTC and benign tumors. Using 
both miR-21 and miR-181a-5p helped to distin-
guish between PTC and FTC with 100 % sensitiv-
ity and 77 % specificity [23].
Prognostic miRNAs
Several studies investigated the potential prog-
nostic value of miRNAs that was summarized 
in Celano et al. Higher expression of miR-146b, 
miR-221 and miR-222 showed association with 
prognostic parameters on tissue level [15]. The 
expression of these miRNAs showed association 
with tumor size, capsular and vascular invasion, 
extra-thyroidal extension, lymph node metasta-
ses and TNM stage [15]. Besides, the overexpres-
sion of miR-146b correlated with multifocality 
and miR-221 with distant metastases as well in 
PTC. Overall survival was significantly decreased 
in patients with higher miR-146b expression in tu-
mor tissue [24]. In a recent study 7 miRNAs (miR-
146b, miR-184, miR-767, miR-6730, miR-6860, 
miR-196a-2 and miR-509-3) were associated 
with the overall survival and miR-184, miR-146b, 
miR-509-3 and lysophosphatidic acid receptor 5 
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(LPAR5) were identified as independent risk fac-
tors for prognosis by multivariate analysis [25]. 
In FTC, the level of miR-221-3p, miR-222-3p, 
miR-222-5p, miR-10b and miR-92a was higher in 
metastatic cases vs. non-metastatic. Regarding 
MTC, Abraham et al. published that miR-183 and 
miR-375 were associated with lymph node me-
tastases, distant metastases and mortality [26]. 
Also, upregulation of miR-224 was described as 
potential prognostic biomarker associated with a 
better outcome in MTC patients [19].
Among circulating miRNAs the level of miR-
222, miR-221, miR-146b and miR-151-5p was 
described to be decreased after tumor removal 
[15]. Serum level of miR-146a-5p and miR-221-
3p was found to be consistent with response to 
therapy, including patients with structural evi-
dence of disease whose thyreoglobulin (Tg) test 
remained negative [13, 15]. Therefore it is sug-
gested that these two miRNAs could be applied 
as post-treatment monitoring biomarker of PTC 
patients, especially when Tg assay results are 
uninformative [13, 15].
ADRENAL TUMORS
Adrenal tumors can develop from the adrenal 
cortex or the medulla. Adrenocortical tumors 
(ACT) are common and their prevalence reaches 
6% after the age of 60 years [27]. Most of them 
are benign (adrenocortical adenomas, ACA) in 
nature. Although the most common tumors, 
so called incidentalomas are non-functioning, 
some are associated with hormone overpro-
duction syndromes (such as Cushing’s, Conn’s 
syndrome, hyperandrogenism). Adrenocortical 
carcinomas (ACC) however, are rare and aggres-
sive tumors (0.5–2/million per year) [27] with 
a dismal prognosis where surgical resection is 
the only curative treatment. The differential di-
agnosis between ACA and localized ACC can be 
challenging as radiological and pathological fea-
tures can be similar but the distinction between 
them is essential due to the completely differ-
ent therapy.
HORMONE PRODUCING 
ADRENAL ADENOMAS
Regarding functional adenomas, peripheral 
blood hormone testing can help in diagnosis. 
In aldosterone producing adenomas (APAs) 
high expression of miR-23 and miR-34a was de-
scribed [27]. He et al. reported 31 miRNAs which 
were significantly differentially expressed in 
APAs when compared to normal adrenal cortex. 
Of these, 23 were downregulated with miR-375 
being the most underexpressed [28]. Between 
expression of miR-375 and miR-7 a strong 
positive correlation was found indicating a po-
tential synergistic function [28]. MiR-375 sub-
stitution in NCI-H295R ACC cell line resulted in 
decreased cell growth and it inhibited its target 
gene metadherin (MTDH). Also, miR-375 expres-
sion was negatively correlated with APA tumor 
size reflecting its potential role as a prognostic 
marker. In cortisol producing adenoma and car-
cinoma, circulating, extracellular, vesicle-associ-
ated miR-22-3p, miR-27a-3p and miR-320b were 
significantly overrepresented compared to non-
functional adenomas [29].
ADRENOCORTICAL CARCINOMAS (ACC)
Diagnostic miRNAs in ACC
Similarly to thyroid tumors, numerous pub-
lications reported differentially expressed 
miRNA profile in ACA and ACC which are ex-
ceedingly summarized by Igaz et al., Cherradi 
et al., and Hassan et al. [30–32]. The most 
frequently reported overexpressed miRNAs 
were miR-483-5p and -3p, miR-503, miR-210 
and miR-184 in ACC vs ACA. Certainly, miR-
483-5p and miR-483-3p have a significant role 
in adrenal tumorigenesis, its gene is located 
in the intron of the insulin like growth factor 
2 (IGF2) gene, a well-known overexpressed 
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gene in ACC. Expectedly, a positive correlation 
was described between miR-483-5p and IGF2 
expression levels [33]. Experiments, however, 
demonstrated that miR-483-5p has an inde-
pendent role in ACC’s pathogenesis as IGF2 
transgenic animals did not develop tumors 
[31]. Indeed, downregulation of miR-483-5p 
(and miR-483-3p) led to decreased prolifer-
ation of ACC cell line [34], and it protected 
cells from apoptosis by targeting proapop-
totic PUMA (p53-upregulated modulator of 
apoptosis or BBC3: BCL2 binding component 
3) [30]. Wang et al, suggested the use of the 
combination of SMAD4 (SMAD family mem-
ber 4) negative/low expression with elevated 
miR-483-3p expression that provided a diag-
nostic specificity of 92.8% for distinguishing 
ACA vs. ACC (while SMAD4 expression itself 
demonstrated high sensitivity of 92%) [35]. 
The overexpression of miR-210 has been also 
documented by several publications [31, 32]. 
This miRNA is widely overexpressed in differ-
ent tumors and it is also called as a “hypox-
amir” due to its upregulation by both hypox-
ia inducible factor 1 subunit alpha and beta 
(HIF1α, HIF1β). It has a role in tumorigenesis 
through regulating arrest of cell prolifera-
tion, repression of mitochondrial respiration, 
arrest of DNA repair, vascular biology, and 
angiogenesis [36]. Among downregulated 
miRNAs in ACC miR-195 has been frequent-
ly reported [31, 32]. As a member of miR-
15/16/195/424/497/6838 family it promotes 
apoptosis together with inhibiting cell prolif-
eration in ACC and other cells targeting cell 
cycle regulators such as cyclin D1 (CCND1) or 
cyclin dependent kinase 6 (CDK6) [31].
Beside adrenocortical tumor tissues, miR-483-
5p was found to be increased in serum, plas-
ma and circulating exosomes derived from pa-
tients with ACC compared to patients with ACA 
[31, 32]. Circulating miR-100, miR-181b, miR-
184, miR-210 and miR-34a were found to be 
upregulated and miR-195, miR-335, miR-376a 
downregulated in ACC samples compared to 
ACA [31, 32]. After tumor removal, the initially 
highly expressed miR-483-5p decreased and low 
level of miR-195-5p increased in blood stream of 
patients with ACC. Therefore, it is suggested that 
these miRNAs directly derived from ACC tissues 
[32]. Interestingly, opposite expression of miR-
NAs in tissue vs. serum was also described in in-
dependent publications too. While miR-34a was 
detected increased in serum and decreased in 
ACC tissues, miR-376a showed the opposite pat-
tern suggesting a potential selecting mechanism 
of extracellular secretion [31, 32]. Assessing di-
agnostic potential of miRNAs Chabre et al. also 
investigated miR-195, miR-335 and miR-376a 
and found that miR-195 showed the highest 
sensitivity (90,9%) and specificity (100%) in dis-
criminating ACC patients [37].
Prognostic miRNAs in ACC
The decreased expression of miR-195 and miR-
497 in ACC was reported to directly regulate 
TARBP2 (TARBP2 subunit of RISC loading com-
plex) and DICER1 (dicer 1, ribonuclease III) ex-
pression in ACC cells therefore contributing to 
a global downregulation of miRNA expression 
[32, 34]. Also, a significant overexpression of 
TARBP2, DICER, and DROSHA (drosha ribonu-
clease III) in ACC compared with ACA or normal 
adrenal cortices were found and inhibition of 
TARBP2 in human ACC cell line resulted in a de-
creased cell proliferation and induction of apop-
tosis [38]. Interestingly, low DICER1 expression 
was also associated with poor clinical outcome 
in adrenocortical carcinoma [30–32].
Lower expression of miR-483-5p in combina-
tion with increased miR-195 level was reported 
as predictor of poor prognosis in ACC [30–32]. 
High expression of miR-503 was associated with 
shorter survival [34], and increased expression 
of miR-210 with ACC clinicopathologic parame-
ters of aggressiveness and a poor prognosis [39, 
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40]. In a recent study, three miRNA clusters 
were identified related to prognosis [40]. 
“Mi1” and “Mi2” miRNA clusters including 11 
upregulated miRNAs located at Xq27.3 and 38 
downregulated miRNAs derived from 14q32 lo-
cus were associated with better prognosis (C1B 
molecular group) while “Mi3” miRNA cluster as-
sociated with poor prognosis (C1A group). 
Using next-generation sequencing expression 
levels of 6 microRNAs (miR-503-5p, miR-483-
3p, miR-450a-5p, miR-210, miR-483-5p and 
miR-421) predicted malignant/non-malignant 
status with over 95% accuracy [41]. In this 
study the best single miRNA for malignancy was 
miR-483-3p [41]. MiR-139-5p and miR-376a 
levels significantly increased in aggressive ACC 
compared with non-aggressive ACC patients 
in tumor samples but not in circulation [37]. 
Additionally, high circulating levels of miR-483-
5p or low circulating levels of miR-195 were as-
sociated with both shorter recurrence-free sur-
vival and shorter overall survival in the study of 
Chabre et al. 2013 [37].
PHEOCHROMOCYTOMA-
PARAGANGLIOMA
Although the localization is different pheochro-
mocytomas (PCC) and paragangliomas (PGL) 
arise from the same type of neural crest tis-
sue of the sympathetic and parasympathetic 
paraganglia [42]. Tumors of the adrenal me-
dulla are called PCCs and neoplasms develop-
ing from thoracic, abdominal or pelvic region 
paraganglia are named as PGLs. It represents 
a rare disease as its estimated incidence is 1-8 
cases per million worldwide annually [42]. PCCs 
and PGLs are usually benign (10-year overall 
survival is around ~96%), however 10% of PCC 
and even 40% of PGL become metastatic re-
sulting in a poorer prognosis (5-year survival 
below 50%) [42]. Unfortunately, there are nei-
ther clear histopathological signs of malignant 
behavior nor efficient therapy for malignant 
PCC/PGL. Therefore, investigating miRNAs as 
potential biomarkers can be useful in this re-
gard. Nonetheless, compared to thyroid and 
adrenocortical neoplasms miRNAs are not so 
extensively investigated in PCC/PGL.
More than 30% of the cases are attributed to 
germline mutation leading to autosomal domi-
nant genetic syndromes such as multiple en-
docrine neoplasia type 2A and 2B caused by 
RET mutations, von Hippel Lindau syndrome 
due to VHL mutations, neurofibromatosis type 1 
with NF1 mutations or hereditary PG syndromes 
caused by mutations of succinate dehydroge-
nase (SDH) genes. Lately, as a result of next-
generation sequencing, novel genes, including 
KIF1b, PHD2, TMEM127, MAX, FH, MDH2, GOT2 
and SLC25A11 were identified in the pathogen-
esis of PCC/PGL [43].
Diagnostic miRNAs
miRNA profile in different genetic subtypes is 
also distinct. Hypoxia induced miR-210 was 
found overexpressed commonly in pseudohy-
poxia-associated PCC/PGLs harboring SDHB and 
VHL mutations. Upregulation of miR-139-3p, 
miR-541, miR-765 and miR-133b was described 
in VHL associated tumors, while miR-96 and 
miR-183 were found to be overexpressed in neo-
plasms with SDHB mutations [30, 44, 45]. NGF 
(nerve growth factor) treatment in vitro in PCC 
cell line significantly decreased the level of miR-
139-3p and miR-210 and led to differentiation 
raising the role of these two miRNAs in tumor 
development [46]. Similarly, through targeting 
ezrin, miR-96 and miR-183 also suppressed cell 
adhesion and differentiation [30]. In MEN2B as-
sociated PCs miR-885-5p was repeatedly found 
to be overexpressed [30]. miR-885-5p regulates 
molecules involved in apoptosis (Casp3) and 
cell cycle (CDK2) [30], and by targeting IGF-
binding proteins its role was supposed in RET 
mutation associated PCC/PGL pathogenesis 
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[30]. Interestingly, miR-137 and miR-382 can be 
considered as general PCC/PGL markers as they 
were found overexpressed in most cases ex-
cept for MAX mutation associated tumors [30]. 
Interestingly, similarly to ACCs, miRNAs coded at 
14q32 genomic region (DLK-MEG3 region) was 
described to be downregulated in MAX mutated 
and a subset of sporadic PC samples as well [42]. 
The DLK-MEG3 locus was reported to be hyper-
methylated in approximately 10% of PC samples 
and the role of downregulated miRNAs located 
here was also proposed [30].
Prognostic miRNAs
Similarly to ACC, miR-483-5p was found to be 
upregulated in malignant PCC/PGL in more 
than one study [30]. Also, the well-known tu-
mor suppressor miR-15a, miR-16 were under-
expressed in malignant PCC vs. benign tumors 
[47]. These miRNAs were downregulated in sev-
eral neoplasms and they are considered tumor 
suppressors by targeting BCL2 and CCND1 [30, 
47]. Igaz et al. described miR-1225-3p overex-
pressed compared to sporadic non-recurring, 
MEN2-, VHL-, and NF1-associated PCs [30]. By 
targeting Notch signaling, the role of miR-1225-
3p is considered in PC tumorigenesis as in in vi-
tro experiments Notch-1 inhibited proliferation 
of PC cell [30].
Compared with benign PCCs, miR-101 level was 
higher in patients with malignant PCCs and the 
level of miR-101 was higher in SDHD mutation 
associated tumors [48]. In discriminating malig-
nant from benign PCs AUCs for miR-101 in all in-
vestigated PCCs samples were 0.79 and 0.77 for 
non-SDHD mutant samples [48]. Another study 
by Patterson et al. also proposed that miR-483-
5p, miR-101, and miR-183 could serve as use-
ful diagnostic markers (AUC: 0.7; 0.78 and 0.82, 
respectively) for distinguishing malignant from 
benign PCCs [44].
PITUITARY TUMORS
Pituitary adenomas are among the most fre-
quent intracranial tumors with a high incidence 
rate, approx. 10–15 % [49]. Although the great 
majority of pituitary tumors are benign they can 
lead to significant morbidity through compress-
ing adjacent structures (visual impairment, 
headache) or by hormonal disturbance (either 
hypo- or hyperfunction). Of these 95% are spo-
radic, only the remaining 5% are associated 
with genetic syndromes such as MEN1, MEN4, 
Carney complex or McCune-Albright syndrome. 
Interestingly, miRNAs are an extensively inves-
tigated field in pituitary tumors. Since the first 
study published in 2005 by Bottoni et al.[50], 
more than a hundred hits have appeared for a 
search with keywords “microrna” AND “pitu-
itary” AND “adenoma” in Pubmed in February, 
2019. These studies broadly evaluated not 
only miRNA signature characteristics of differ-
ent types of pituitary adenomas but also target 
genes and miRNA function as well. Accordingly, 
several reviews summarizing the expression 
profile and role of tissue miRNAs widely inves-
tigated in pituitary adenoma have been pub-
lished, one of the most recent by Feng et al. in 
2018 [51] who extensively summarized miRNAs 
reported in pituitary adenomas dissected by 
adenoma subtypes. Here, we aim to highlight 
the roles of miRNAs by their targets’ function. 
Although the expression profile and role of tis-
sue miRNAs are widely investigated in pituitary 
adenoma, we lack information about the diag-
nostic potential of miRNAs present in circula-
tion. Pituitary adenomas are hormone secreting 
which give an excellent opportunity to monitor 
tumor growth and function by hormone tests, 
therefore the role of miRNAs might be less im-
portant. However, regarding non-functional 
pituitary adenomas a blood-based miRNA bio-
marker could help the diagnosis and patient 
follow-up after surgery.
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Diagnostic miRNAs
Pituitary subtype-specific miRNA profile was 
described by several studies [51].
In GH producing adenomas several miRNAs 
target insulin growth factor binding proteins 
(IGFBP-3, -6, -7) that regulates organ develop-
ment and growth [51]. The overexpressed miR-
26a has a key role in the pathogenesis of GH-
secreting adenoma by directly regulating PI3K/
Akt signaling pathway and LEF-1 that is involved 
in anterior pituitary development [51]. The 
overexpression of Pituitary Tumor-Transforming 
Gene 1 (PTTG1) was demonstrated in ~90% of 
pituitary adenoma independently of adenoma 
type. A set of downregulated miRNAs (miR-126, 
miR-381, miR-665, miR-300, miR-381, miR-329) 
is suggested to contribute to PTTG1 overexpres-
sion as restoring their level in vitro led to sup-
pressed viability and proliferation of pituitary 
cells [52]. High Mobility Group AT-Hook Protein 
2 encodes a non-histone chromosomal high mo-
bility group (HMG) protein, as a transcriptional 
regulator it controls cell cycle and pituitary cell 
proliferation. Numerous miRNAs were identi-
fied targeting HMGA1 and 2 in GH, PRL and non-
functioning pituitary adenomas [51]. In sporadic 
GH-producing adenomas miR-34a and miR-107 
were found to regulate AIP a well-known tumor 
suppressor frequently mutated in familial pitu-
itary adenomas.
In corticotroph adenomas miR-26a was mas-
sively overexpressed compared to normal pi-
tuitary. MiR-26a downregulated Cyclin A and 
Cyclin E and it targeted PRKCD (protein kinase C 
delta) that was reported to suppress ACTH se-
creting pituitary cells [51].
In prolactinomas HMGA1 and 2 as a target of sev-
eral miRNAs were also validated. Interestingly 
the expression of miR-432 were found to be 
positively correlated with serum prolactin [51]. 
The role of downregulated miR-410 was also 
proved in pathogenesis of prolactinoma by tar-
geting Cyclin B1 [51].
In non-functioning pituitary adenomas (NFPAs) 
the role of HMGA1 and 2 proteins also has to be 
mentioned regulated by several miRNAs [51]. 
Cell cycle in NFPAs is regulated in G2M transition 
by miRNAs through targeting Wee1 and CDC25A 
[53]. The TGFβ signaling is also controlled by 
miRNAs through SMAD3 [54]. Additionally, miR-
106b influenced migration and invasion of pitu-
itary adenoma cells via regulating PTEN and fur-
ther activity of the PI3K/AKT signaling pathway 
and MMP-9 expression [51].
In pituitary carcinoma metastasis expression 
of miR-20a, miR-106b and miR-17-5p were 
increased compared to the primary neoplasm 
and these miRNAs were proved to be involved 
in pituitary carcinoma metastasis by attenuating 
PTEN and TIMP2 (TIMP metallopeptidase inhib-
itor 2) [55]. In ACTH producing carcinomas miR-
493 was significantly upregulated compared to 
ACTH adenomas while miR-122 overexpressed 
in both corticotroph adenomas and carcinomas 
compared to normal pituitary [56]. LGALS3 and 
RUNX2 are both predicted targets of miR-493 
and these genes have been shown to have roles 
in pituitary tumor cell growth [56].
Prognostic miRNAs
Level of several miRNAs (miR-24, miR-34a, miR-
93, miR-148-3p, miR-152, miR-132, miR-15a, 
and miR-16) are significantly lower in invasive 
pituitary adenomas compared with non-inva-
sive ones [57]. In prolactinomas, miR-183 was 
found downregulated in aggressive tumors and 
it inhibited tumor cell proliferation by inhibiting 
KIAA0101 that is involved in cell cycle activation 
and inhibition of p53-p21 mediated cell cycle 
arrest [58]. In corticotroph adenomas miR-93-
3p, miR-93-5p, miR-25-3p and miR-106b-5p 
were detected to be overexpressed in invasive 
tumors compared to non-invasive ones through 
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targeting MCM7 the overexpression of these 
miRNAs led to increased invasiveness and un-
favorable outcomes after resection [51, 59]. 
Patients with corticotroph adenomas with de-
creased level of miR-141 had higher chance of 
remission [60].
In NFPAs several miRNAs showed correlation 
with tumor size some of the (miR-450b-5p, miR-
424, miR-503, miR-542-3p, miR-629, and miR-
214) were underexpressed and target SMAD3 
[54]. In invasive adenomas expression levels 
of miR-181b-5p, miR-181d, miR-191-3p, and 
miR-598 were upregulated, and the expression 
levels of miR-3676-5p and miR-383 were down-
regulated [61]. In GH3 cells Caveolin-1 (CAV1) 
was reported to promote invasion while silenc-
ing CAV1 indirectly induced miR-145, miR-124, 
and miR-183 that suppressed the migration and 
invasion of pituitary adenoma cells through tar-
geting FSCN1, PTTG1IP and EZR, respectively 
[57].
NEUROENDOCRINE TUMORS (NETs)
Neuroendocrine tumors (NETs) consist of het-
erogeneous neoplasms of different origin aris-
ing from neuroendocrine cells throughout the 
body (most commonly from the lungs, pan-
creas, small intestine, and rectum). Gastro-
entero-pancreatic NETs (GEP-NETs) represent 
less than 1% of digestive cancers and 7-21% of 
all neuroendocrine neoplasms [62]. Lung NETs 
originate from pulmonary neuroendocrine cells 
accounting for approximately 25% of primary 
lung neoplasms. Lung NETs classified into the 
following subtypes: typical carcinoids (TCs, well 
differentiated, low-grade); atypical carcinoids 
(ACs, well-differentiated, intermediate-grade); 
large cell neuroendocrine carcinomas (LCNECs, 
poorly differentiated, high-grade); and small 
cell lung cancer (SCLCs, poorly differentiated, 
high-grade) [63]. NET as a heterogeneous group 
have different behavior and prognosis but they 
express neuroendocrine markers such as chro-
mogranin A (CgA) and synaptophysin. Based on 
the World Health Organization (WHO) classifica-
tion the prognosis is characterized by the grade 
of neuroendocrine differentiation and the pro-
liferative index (Ki-67) from G1-G3. However, 
guidelines indicate that prognosis is also influ-
enced by several other factors, such as patient 
age, tumor site, metastatic spread and hormon-
al production [64]. Unfortunately as more than 
80% of patients usually present with metastatic 
disease, NET prognosis is poor, due to the rela-
tive lack of effective therapy [63, 64]. Among 
circulating biomarkers, CgA has been measured 
in several NETs, but its value as a prognostic bio-
marker in NETs is limited [64], therefore identifi-
cation of prognostic factors to predict outcome 
would be fundamental.
Diagnostic miRNAs
Interestingly, little information is available re-
garding miRNA profile in gastric NETs (gNETs), 
however it was described that gastrin-induced 
miR-222 overexpression resulted in reduced 
p27, which in turn caused actin remodeling and 
increased migration in human stably CCK2 re-
ceptor expressing gastric adenocarcinoma cell 
line [65].
In circulation, serum miR-222 expression was 
increased in hypergastrinemic patients with au-
toimmune atrophic gastritis and type 1 gastric 
NET. Because its level decreased in patients af-
ter CCKR2 agonist treatment miR-222 was pro-
posed to be a promising biomarker for gastrin 
induced premalignant changes in the stomach 
[65].
However, different miRNA sets with altered ex-
pression were described regarding pancreatic 
NET (pNET), comparing functional, nonfunc-
tional NET, normal pancreas, normal pancre-
atic islets in any combinations that is reviewed 
in detail by Malczewska et al. and Zatelli et al. 
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[64, 65]. The overexpressed miR-103, miR-107 
and the underexpressed miR-155 discriminated 
sporadic pancreatic NET (insulinoma and non-
functioning) from acinar cell carcinomas. The 
role of downregulated miR-155 was suggested 
in pathogenesis by targeting proapoptotic tu-
mor protein p53 inducible nuclear protein 1 
(TP53INP). Also, miR-144/451 cluster and miR-
21 was found overexpressed compared to nor-
mal pancreatic islets [65]. MiR-204 was found 
primarily expressed in insulinomas and corre-
lated with immunohistochemical expression 
of insulin [66]. Interestingly, several miRNAs 
located at 14q32 region showed dysregulated 
expression, including miR-144/451 cluster [65]. 
Interestingly, these miRNAs showed overex-
pression in insulinomas compared to other 
endocrine tumors where miRNAs of this re-
gion are frequently downregulated. In in vitro 
experiments miR-144 induced cell proliferation 
in murine pancreatic β cells and regulated Akt 
signaling by targeting PTEN [65]. Additionally, 
miR-451 also promoted cell proliferation by 
regulating cell cycle through targeting p19 [67]. 
Overexpression of miR-21 were reported over-
expressed in pNET [65, 66]. Expression of miR-
642 correlated with Ki67 (MiB1) score and miR-
210 correlated with metastatic disease [68].
13 miRNAs were identified by comparing serum 
from pNET patients and healthy volunteers and 
miR-193b was up-regulated in both pNET tis-
sue and serum when compared to controls de-
scribed by Thorns et al. [68]. In addition, miR-
1290 showed overexpression in pNETs and the 
latter could accurately distinguish patients with 
low-stage pancreatic cancer from healthy con-
trols and subjects with chronic pancreatitis [69].
MiRNA profile of small bowel NET (sbNET) was 
also investigated, however fewer experimental 
information are available regarding miRNA’s 
function studies and target validation. MiR-
7-5p, miR-182, miR-183 and miR-96-5p were 
found to be upregulated in sbNET compared to 
normal small bowel consequently in different 
studies [65]. Furthermore, miR-182, miR-183 
and miR-96 overexpressed in NET metastases 
compared to primary tumors [65]. Similarly, up-
regulation of miR-196a was described in numer-
ous studies however its role in cell proliferation 
could not be confirmed [65, 69]. In addition, the 
downregulation of miR-129-5p and miR-133a 
was also established in sbNET metastases vs. 
primary tumors [65].
Similarly to tissue, overexpression of miR-182, 
miR-196a and miR-200a and downregulation 
of miR-31, miR-129-5p and miR-133a were de-
tected in blood of sbNET patients and the level 
of some of them changed upon somatostatin 
treatment [65].
Similarly to sbNET, in appendiceal carcinoids 
without metastases low levels of miR-96 and 
high levels of miR-133a were detected [65]. In 
colorectal NET (cNET) patients underexpression 
of miR-186 was found in tumor tissue, blood 
and stool samples compared to controls. In par-
allel, PTTG1 upregulation was detected in the 
same samples together with decreased miR-
186 expression therefore the authors suggested 
that upregulation of PTTG1 was induced by the 
loss of miR-186 [70].
Interestingly, based on miRNA expression pro-
file analysis common origin for pulmonary carci-
noids and GI-NETs was suggested by Yoshimoto 
et al. [71]. 
Lung NETs. The expression profiles of pulmo-
nary carcinoids and SCLCs were quite different, 
indicating the distinct genesis of these neuroen-
docrine neoplasms [71].
Prognostic miRNAs
A study by Sadanandam et al. identified mo-
lecular subtypes of pNETs (islet-like, inter-
mediate and metastasis-like primary types) 
[72]. As these subtypes exhibit distinct meta-
bolic profiles marked by differential pyruvate 
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metabolism, substantiating the significance of 
their separate identities they may have role to 
predict different behavior. Expectedly, the three 
subtypes have distinct mRNA and miRNA sig-
natures as well [72]. Roldo et al. reported the 
overexpression of miR-21 as positively correlat-
ed with Ki-67 proliferation index and presence 
of liver metastases [66]. Besides, expression of 
miR-642 was also described to correlate with 
Ki67 index score while miR-210 correlated with 
metastatic disease [68]. Additionally miR-196a 
was identified as prognostic factor in pNET as its 
expression significantly associated with stage, 
and mitotic count [64]. Also, high miR-196a 
level was associated with decreased overall sur-
vival and disease-free survival. The hazard ratio 
for recurrence of patients with high miR-196a 
expression was 16.267 [73].
In sbNET increased plasma miR-21 and de-
creased miR-150-5p were characteristic to met-
astatic tumors [74]. In line with this, low plasma 
miR-21 and high miR-150-5p levels were asso-
ciated with significantly prolonged overall sur-
vival [74]
In rectal carcinoids miR-885-5p was identified 
as upregulated in tumors with lymphovascular 
invasion. Also, high miR-885-5p expression was 
independently associated with lymphovascular 
invasion. Therefore miR-885-5p is suggested as 
a potential biomarker for predicting malignancy 
[75].
Regarding NET in the lung Zatelli et al. thor-
oughly summarized miRNAs with prognostic 
role [64]. miR-150 and miR-886-3p were found 
downregulated while miR-92a2* and miR-7 
upregulated in SCLC that showed correlation 
with overall or disease-free survival. The lat-
ter miRNAs were found to be associated with 
chemoresistance too [64]. In other publications 
including typical, atypical carcinoids and large 
cell neuroendocrine carcinomas the upregulat-
ed miR-21 and the downregulated miR-409-3p, 
miR-409-5p, and miR-431-5p correlated with 
the presence of lymph node metastases and set 
of other 5 upregulated miRNAs with overall sur-
vival [64].
COMMON miRNAs DETECTED  
IN VARIOUS ENDOCRINE TUMORS
Although miRNAs’ expression and their func-
tions are tissue specific, discussing common 
miRNAs among different endocrine tumors can 
still be an interesting aspect reflecting potential 
common pathomechanism. For instance, miR-
210 was overexpressed in several endocrine tu-
mors, such as ACC and PCC/PGL [30, 31]. Also, 
its increased expression seems to be an unfa-
vorable prognostic factor correlating clinico-
pathologic parameters of aggressiveness and a 
poor prognosis in ACC and in pNET [39, 40, 68]. 
Usually, the increased expression of miR-210 
might be a consequence of hypoxic environment 
within tumor tissues or activation of pseudohy-
poxia signaling pathway in PPC/PGL. As a gen-
eral phenomenon increase of miR-210 was also 
described in other, non-endocrine solid tumors 
(i.e. breast, lung, head and neck, pancreatic and 
glioblastoma).
Overexpression of miR-483-5p and miR-483-3p 
in tissues and in circulation (serum, plasma and 
exosomes) is almost a unique characteristic of 
ACC and is considered as a prognostic marker 
[30, 31, 32, 33]. It predicted malignant/non-ma-
lignant status and it associated with both short-
er recurrence-free survival and shorter overall 
survival. Interestingly, not only for tumors of 
adrenal cortex but for tumors originated from 
adrenal medulla (PCC/PGL) miR-483-5p is also 
proposed as useful diagnostic markers for ma-
lignancy [30].
Two well-known tumor suppressor miRNAs: 
miR-15a and miR-16 are downregulated in pi-
tuitary adenomas and in PCC where they were 
described to be able to discriminate benign 
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Figure 1 miRNAs coded at 14q32 is commonly dysregulated in endocrine neoplasms: 
downregulated in neuroendocrine tumors, pituitary adenomas, thyroid 
cancer and adrenocortical carcinoma (indicated by green arrows) 
and overexpressed in pheochromocytomas (showed by red arrow)*
*At 14q32 region paternally imprinted genes (DLK1, RTL1, and DIO3) are illustrated by black, maternally imprinted 
noncoding RNAs (MEG3, anti-RTL1, and MEG8) are represented by grey boxes. 
Lollipops indicate methylation sites at DLK1 promoter region, intergenic differentially methylated region (IG-DMR), 
and MEG3 differentially methylated region (MEG3-DMR) region. MiRNAs at 14q32 region are located in 2 clusters 
separated by a small nucleolar RNA (snoRNA) cluster. miRNA cluster 1 contains 10 miRNAs and cluster 2 encodes 
more than 40 miRNAs. Therefore, alteration in methylation, chromatin remodeling, genomic imprinting imbalance or 
structural loss can lead to dysregulated miRNA expression. 14q32 miRNAs influence cell proliferation, cell adhesion, 
and migration through regulating targets involved in transforming growth factor beta signaling or epithelial–mesen-
chymal transition.
TGFBR2: Transforming Growth Factor Beta Receptor 2; ROCK2: Rho Associated Coiled-Coil Containing Protein Kinase 2; 
ICK: Intestinal Cell Kinase; CDH11: Cadherin 11; CDK5: Cyclin Dependent Kinase 5; TWIST1: Twist Family BHLH Tran-
scription Factor 1; cMYC: MYC Proto-Oncogene; RTL1: retrotransposon-like gene RTL1; RTL1-AS: retrotransposon-like 
gene RTL1 antisense; DLK1: Delta Like Non-Canonical Notch Ligand 1; MEG3: Maternally Expressed 3; 
MEG8: Maternally Expressed 8, Small Nucleolar RNA Host Gene; DIO3: Iodothyronine Deiodinase 3.
eJIFCC2019Vol30No2pp146-164
Page 160
Henriett Butz, Attila Patócs
MicroRNAs in endocrine tumors
and malignant forms of the disease [47, 51]. In 
addition, the lost expression of general tumor 
suppressor miRNAs targeting BCL2 and CCND1 
have been described in other, non-endocrine 
tumors as well [30, 47].
Additionally, Pituitary Tumor-Transforming Gene 
1 (PTTG1) is another target gene that is regulated 
by miRNAs in endocrine tumors. Several miRNAs 
(miR-126, miR-381, miR-665, miR-300, miR-381, 
miR-329) are suggested to contribute to PTTG1 
overexpression in pituitary adenomas [51], that 
is also upregulated in colorectal NET by the loss 
of miR-186 [70]. However, PTTG1 overexpres-
sion is not unique for endocrine tumors as it was 
described in several other malignancies with 
prognostic potential. 
MiR-21, a widely investigated oncomiR, has 
been found up-regulated in many types of hu-
man tumors. Indeed, in lung NET and pNET it 
was described overexpressed and in pNET its ex-
pression positively correlated with proliferation 
index and with metastases [65, 66]. Additionally, 
its level was reported elevated in circulation in 
sbNET where it was described to be characteris-
tic to metastatic tumors and associated with sig-
nificantly prolonged overall survival [74]. In fol-
licular thyroid cancer plasma level of exosomal 
miR-21 helped to distinguish between FTC and 
benign tumors [23]. 
Similarly to miR-21, miR-222 is differentially ex-
pressed in several endocrine tumors, such as in 
gastric NET (where it is induced by gastrin) and 
in thyroid cancer (both papillary and anaplas-
tic) [13, 15, 18, 65], whereas in follicular thyroid 
cancer the tissue level of miR-222 was prognos-
tic (higher in metastatic cases vs. non-metastat-
ic). In the blood stream of PTC patients, miR-222 
expression significantly decreased after surgery 
[21].
CONCLUSIONS AND FUTURE PERSPECTIVES
It is obvious that miRNAs are potentially useful 
and promising tissue and circulating biomark-
ers. They are extensively investigated in differ-
ent neoplasms including tumors of the neuro-
endocrine system. Interestingly, miRNAs coded 
at 14q32 region seems to be dysregulated in al-
most all endocrine neoplasms (Figure 1) and sev-
eral other tumors. This region is frequently found 
hypermethylated in cancer compared to normal 
tissues. The downregulation of miRNAs located 
at 14q32 region shows important correlations 
with poor prognosis and aggressiveness in differ-
ent cancer types. Studies also suggest chromatin 
remodeling by lncRNA-mediated mechanisms 
in this region beside DNA methylation that may 
also influence miRNA expression. Additionally, 
as 14q32 is an imprinted region and imprinting 
imbalance could also result in alteration of pater-
nally and maternally expressed genes. 
Regarding their application to routine diagnostics 
thyroid tumors and FNAB samples seem to be in-
vestigated the most intensively. Although high 
sensitivity and diagnostic accuracy of miRNAs 
have been reported in thyroid cancer which may 
be suitable for differentiation of benign vs malig-
nant thyroid nodules, routine use of miRNAs as 
biomarkers has not been widespread yet either 
in thyroid or other endocrine and non-endocrine 
tumors. In literature it is suggested that this may 
be due to challenging preanalytics, especially in 
case of bio-fluids. Additionally, there are no IVD-
CE (IVD: applicable for In Vitro Diagnostic, CE: 
complies with the essential requirements of the 
relevant European health, safety and environ-
mental protection legislations) marked assays to 
measure miRNAs in clinical care. That also may 
delay miRNAs’ application as potential diagnostic 
biomarkers. 
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However, regarding thyroid nodules there are 
common miRNAs among different studies dis-
criminating benign and malignant nodules (e.g. 
miR-221, miR-222, and miR-146b). These miR-
NAs should be further investigated as potential 
candidates for clinical use.
In pituitary neoplasms, however there is the 
most information gathered regarding the patho-
genesis and miRNA-regulated networks, there is 
basically no information on miRNAs in biofluids. 
It can be a consequence of negative results or 
the difficulty of sample group homogenization 
due to the different adenoma groups especially 
in the light of the 2017 WHO classification. In 
adrenocortical carcinoma the role of one miRNA 
(miR-483-5p) has been repeatedly proved by 
several studies in both tissue level and in circula-
tion. And finally, the prognostic role of miRNAs 
is also intensively investigated in NETs however, 
again, due to the heterogeneous tumor group 
there is still a need for data regarding the ap-
plication of any miRNA biomarker in clinical use. 
Behind the discrepant results found in literature 
not only the tumor heterogeneity but also the 
differences in study design and technical imple-
mentation could be suspected. Regarding cir-
culating biomarkers, currently there are many 
biological (age, gender, BMI, smoking status, 
disease stage, other accompanying illnesses, 
medications, etc.) and technical (serum, plas-
ma, extracellular vesicle as source, different 
nucleic acid extraction methods, miRNA detec-
tion methods, etc.) factors known and unknown 
which need standardization and harmonization 
in order to establish evidences before applica-
tion of miRNAs as biomarkers.
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